PrimoGAIA
PrimoGaia opens up a new pathway in Magnetic Resonance Imaging (MRI) by initiating the concept of in vivo “enzymatic imaging” for a better understanding of human physiology, early detection and prognosis of diseases, monitoring of therapeutic treatment.
The project
| 7 partners 4 countries H2020 FET Open |
Start: 01-12-2019 end: 31-05-2023 |
News
#magnetic resonance imaging (MRI), #dynamic nuclear polarization (DNP), #overhauser MRI (OMRI), #enzyme activity, #ultra-low field, #contrast agents, #inflammatory diseases, #enzymatic mapping, #cost efficient sytems, #medical engineering
Nanoscale journal: Functionalized silica nanoplatform as a bimodal contrast agent for MRI and optical imaging
Published in the Nanoscale journal
...
Journal of Magnetic Resonance: Enzymatic activity monitoring through dynamic nuclear polarization in Earth magnetic field
Published in the Journal of Magnetic Resonance
...
Periodic Reporting for period 1: 2019-12-01 to 2020-11-30
Periodic Reporting for period 1 - PRIMOGAIA
...
PrimoGAIA 2nd Steering Committee meeting
The PrimoGAIA 2nd Steering Committee was held in Bordeaux, France, on the 13th and 14th of September 2021
...
PrimoGAIA considered as Excellent Science Innovation
Good news for the PrimoGAIA project with five of its innovations recognised as excellent by the EU Innovation Radar
...
The PrimoGAIA’s ”First Kernel” arrived in Bordeaux
The PrimoGAIA’s ”First Kernel” arrived in Bordeaux and has been successfully installed at the CRMSB laboratory .
...
PrimoGAIA Data Management Plan
The DMP has been released in compliance with the Horizon 2020 FAIR DMP
...
